ITMN—What was consequential about the passage in question was that it was the first time I heard ITMN admit that ritonavir boosting closes off some options from a business standpoint. Up until now, the company line had always been that ritonavir boosting was a non-issue.
p.s. I think you’re right that it was Seiwert, not Welch, who spilled the beans.
Market Data 
Markets 
AI
